TELBIVUDINE - Generic Drug Details

What are the generic sources for telbivudine and what is the scope of freedom to operate?

Telbivudine is the generic ingredient in one branded drug marketed by Novartis and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for telbivudine.

Summary for TELBIVUDINE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	2
Drug Master File Entries:	2
Raw Ingredient (Bulk) Api Vendors:	82
Clinical Trials:	84
DailyMed Link:	TELBIVUDINE at DailyMed

Recent Clinical Trials for TELBIVUDINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chinese University of Hong Kong	PHASE4
Mahidol University	Phase 4
Lai Wei	Phase 2

See all TELBIVUDINE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for TELBIVUDINE

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for TELBIVUDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TYZEKA	telbivudine	SOLUTION;ORAL	022154-001	Apr 28, 2009		DISCN	No	No
Novartis	TYZEKA	telbivudine	TABLET;ORAL	022011-001	Oct 25, 2006		DISCN	Yes	No

Expired US Patents for TELBIVUDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TYZEKA	telbivudine	TABLET;ORAL	022011-001	Oct 25, 2006	6,566,344
Novartis	TYZEKA	telbivudine	SOLUTION;ORAL	022154-001	Apr 28, 2009	6,395,716
Novartis	TYZEKA	telbivudine	SOLUTION;ORAL	022154-001	Apr 28, 2009	7,795,238
Novartis	TYZEKA	telbivudine	TABLET;ORAL	022011-001	Oct 25, 2006	7,589,079
Novartis	TYZEKA	telbivudine	TABLET;ORAL	022011-001	Oct 25, 2006	7,858,594
Novartis	TYZEKA	telbivudine	TABLET;ORAL	022011-001	Oct 25, 2006	6,444,652

EU/EMA Drug Approvals for TELBIVUDINE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Sebivo	telbivudine	EMEA/H/C/000713Sebivo is indicated for the treatment of chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.Initiation of Sebivo treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate.	Withdrawn	no	no	no	2007-04-24

Market Dynamics and Financial Trajectory for TELBIVUDINE

Last updated: February 13, 2026

Telbivudine (brand name: Tyzeka, Sebivo) is an antiviral medication developed for the treatment of chronic hepatitis B virus (HBV) infection. Since its approval in 2006, the drug's market performance, competitive landscape, and financial prospects have been shaped by regulatory, clinical, and market-driven factors.

---

What Are the Current Market Dynamics for Telbivudine?

Market Size and Demand Drivers

The global hepatitis B treatment market was valued at approximately USD 1.4 billion in 2022. The increasing prevalence of chronic HBV, estimated at 292 million individuals worldwide [1], drives the demand for antiviral therapies including telbivudine.

• Geographical Markets: The Asia-Pacific region accounts for the largest share due to higher HBV prevalence—up to 8% in some countries like China and Vietnam. North America and Europe represent smaller segments but have higher treatment adoption rates.

• Treatment Guidelines: The World Health Organization recommends antiviral therapy for HBV patients with high viral loads or signs of liver damage. Telbivudine’s once-daily dosing appeals to adherence.

Competitive Landscape

Telbivudine faces competition from several first-line therapies:

Drug	Class	Market Share (2022)	Status
Entecavir	Nucleoside analog	46%	Market leader in HBV therapy
Tenofovir	Nucleoside analog	38%	Increasing due to safety profile
Telbivudine	Nucleoside analog	5%	Declining presence, limited availability
Others (e.g., lamivudine)	Nucleoside analog	11%	Declining due to resistance issues

Note: Data sourced from IQVIA (2022).

Regulatory and Patent Status

• Regulatory Approvals: Telbivudine was approved by the U.S. FDA in 2006. It is marketed primarily in select countries; however, it does not hold widespread approval status worldwide.

• Patent Status: The original patents expired in many markets by 2016, opening pathways for generic competitors. This has resulted in price erosion and reduced revenue potential.

How Has Telbivudine's Financial Trajectory Evolved?

Revenue Performance

• Peak sales reportedly exceeded USD 100 million annually around 2008-2010 in markets like the US and Europe.

• Post-2014, global sales declined sharply, correlating with shifts to preferred therapies (e.g., entecavir, tenofovir). Reports indicate sales fell below USD 20 million by 2020.

Market Withdrawal and Production

• Major pharmaceutical companies, including GlaxoSmithKline (GSK), which marketed Tyzeka/Sebivo, withdrew the drug from certain markets due to declining sales, replacement by more effective or safer options.

• Generic versions flooded markets post-patent expiry, further suppressing profitability.

Research and Development Investments

• Limited ongoing R&D efforts for telbivudine indicate low current investment, reflecting diminishing commercial viability.

• No recent major clinical trials; the focus shifted toward more advanced therapies with improved safety profiles and resistance management.

What Are the Future Considerations?

Patent Expiry and Generic Competition

• Most markets experienced patent expiration by 2016-2018; generic versions now comprise most sales in regions where the drug remains available.

Regulatory Reassessments

• No significant recent regulatory re-approvals or extensions reported. Without new clinical data or indications, future market opportunities are limited.

Potential for Niche or Combination Use

• Research into combination therapies continues, primarily with drugs like tenofovir or entecavir, but telbivudine's role remains marginal.

• Possible niche application in specific populations is unlikely to restore significant market share.

Key Market Trends Summary

Trend	Impact
Increased competition from tenofovir and entecavir	Reduced market share for telbivudine
Patent expiries (2016-2018)	Price erosion, increased generics penetration
Shift in clinical guidelines	Favoring drugs with better resistance profiles
Limited pipeline development	Reduced long-term market prospects

---

Key Takeaways

• Telbivudine experienced rapid growth following approval in 2006 but saw its market share decline due to competition and resistance issues.
• Revenue declined from over USD 100 million annually in the late 2000s to below USD 20 million by 2020.
• Patent expiries and generic availability significantly diminish potential earnings.
• The drug’s future remains constrained, with negligible R&D activity and limited regulatory support.
• The hepatitis B treatment market is consolidating around tenofovir and entecavir, with newer therapies like tenofovir alafenamide gaining favor.

---

FAQs

1. Is Telbivudine still marketed globally?
Limited markets continue to market telbivudine, mainly where generic versions are available or regulatory approvals persist. However, its use has significantly declined.

2. What are the main reasons for telbivudine’s declining market?
Efficacy concerns, resistance development, and competition from more potent and safer drugs like tenofovir and entecavir.

3. Are there ongoing clinical trials involving telbivudine?
No significant new trials are underway; research has shifted toward other antiviral agents.

4. Can telbivudine be used in combination therapy?
It has been studied in combinations, but current guidelines favor other agents due to resistance issues.

5. What economic factors influence the future of telbivudine?
Patent expiration, generic competition, and regulatory status determine market viability and pricing potential.

---

References

1. World Health Organization. "Global Hepatitis Report," 2017.
2. IQVIA. "Global Overview of Hepatitis B Market," 2022.
3. U.S. Food and Drug Administration. "Tyzeka (telbivudine) approval history," 2006.
4. GSK Annual Reports. "Product Portfolio and Market Performance," 2010-2015.